Ephrin-A4, which is overexpressed in TNBC and ovarian cancer, was selected as a therapeutic target, and a cell line transfected with the ephrin-A4 gene was challenged with two versions of biotinylated anti-ephrin-A4 coupled to Streptavidin-ZAP. This evidence concerns the gene EFNA4 and ovarian carcinoma.